A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration
暂无分享,去创建一个
K. Horie-Inoue | S. Inoue | T. Hikichi | R. Yamada | F. Matsuda | A. Tsujikawa | A. Negi | H. Iijima | S. Ooto | N. Yoshimura | K. Yamashiro | S. Yoneya | R. Obata | Kanji Takahashi | K. Miyata | H. Tamura | Chikako Hara | S. Kishi | A. Oishi | M. Yoshikawa | M. Miyake | H. Koizumi | T. Iida | M. Ogasawara | T. Iwata | T. Awata | T. Sekiryu | M. Saito | S. Honda | A. Miki | Wataru Matsumiya | M. Kano | K. Mori | A. Ohira | Y. Yanagi | Naoshi Kondo | Y. Nagai | K. Azuma | I. Nakata | Yoichi Sakurada | Seigo Yoneyama | Wataru Kikushima | Taku Sato | K. Sayanagi | F. Gomi | Hidenori Takahashi | H. Kitamei | H. Matsumoto | Ryo Mukai | A. Obana | Yasushi Kataoka | Y. Koyama | T. Tsuchihashi | Masayuki Ohnaka | S. Kabasawa | Kazuhiro Ueyama | Hiroaki Bessho | Xue Tan | Sho Kabasawa
[1] P. Xie,et al. Genetic Association with Response to Intravitreal Ranibizumab for Neovascular Age-Related Macular Degeneration in the Han Chinese Population , 2013, Ophthalmologica.
[2] S. Piermarocchi,et al. Combined effects of genetic and non‐genetic risk factors affect response to ranibizumab in exudative age‐related macular degeneration , 2015, Acta ophthalmologica.
[3] M. Savolainen,et al. INTERLEUKIN 8 PROMOTER POLYMORPHISM PREDICTS THE INITIAL RESPONSE TO BEVACIZUMAB TREATMENT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION , 2013, Retina.
[4] W. Berger,et al. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. , 2011, Investigative ophthalmology & visual science.
[5] H. Aounallah-Skhiri,et al. Y402H Polymorphism in Complement Factor H and Age-Related Macular Degeneration in the Tunisian Population , 2013, Ophthalmic Research.
[6] U Chakravarthy,et al. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. , 2014, Ophthalmology.
[7] Dae Hyun Lee,et al. Pharmacogenetic Influence of LOC387715/HTRA1 on the Efficacy of Bevacizumab Treatment for Age-Related Macular Degeneration in a Korean Population , 2012, Korean journal of ophthalmology : KJO.
[8] Jiayan Huang,et al. VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). , 2014, JAMA ophthalmology.
[9] I. Constable,et al. Complement factor H Y402H and C-reactive protein polymorphism and photodynamic therapy response in age-related macular degeneration. , 2009, Ophthalmology.
[10] M. Brantley,et al. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy , 2009, Eye.
[11] A. Tsujikawa,et al. Two-year visual outcome of ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy , 2015, Graefe's Archive for Clinical and Experimental Ophthalmology.
[12] Yonghua Hu,et al. Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population. , 2012, Pharmacogenomics.
[13] R. González-Sarmiento,et al. Predictive value of VEGF A and VEGFR2 polymorphisms in the response to intravitreal ranibizumab treatment for wet AMD , 2014, Graefe's Archive for Clinical and Experimental Ophthalmology.
[14] P. Tommila,et al. The Effect of Complement Factor H Y402H Polymorphism on the Outcome of Photodynamic Therapy in Age-related Macular Degeneration , 2007, European journal of ophthalmology.
[15] P. Tommila,et al. Vascular endothelial growth factor gene variation and the response to photodynamic therapy in age-related macular degeneration. , 2010, Ophthalmology.
[16] R. Yamada,et al. Genetic variants in pigment epithelium-derived factor influence response of polypoidal choroidal vasculopathy to photodynamic therapy. , 2011, Ophthalmology (Rochester, Minn.).
[17] Ivana K. Kim,et al. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). , 2013, Ophthalmology.
[18] Chun-Fang Xu,et al. GENETIC FACTORS ASSOCIATED WITH RESPONSE TO INTRAVITREAL RANIBIZUMAB IN KOREAN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2014, Retina.
[19] M. McKibbin,et al. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration , 2011, British Journal of Ophthalmology.
[20] I. Chowers,et al. Sequence variants in HTRA1 and LOC387715/ARMS2 and phenotype and response to photodynamic therapy in neovascular age-related macular degeneration in populations from Israel , 2008, Molecular vision.
[21] A. Tsujikawa,et al. VEGF gene polymorphism and response to intravitreal bevacizumab and triple therapy in age-related macular degeneration , 2011, Japanese Journal of Ophthalmology.
[22] Christoph Ehlken,et al. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV , 2016, British Journal of Ophthalmology.
[23] J. Jonas,et al. Role of vascular endothelial growth factor polymorphisms in the treatment success in patients with wet age-related macular degeneration. , 2012, Ophthalmology.
[24] A. Tsujikawa,et al. Factors Associated with Recurrence of Age-Related Macular Degeneration after Anti-Vascular Endothelial Growth Factor Treatment: A Retrospective Cohort Study. , 2015, Ophthalmology.
[25] J. Duker,et al. Predictors of Response to Intravitreal Anti-Vascular Endothelial Growth Factor Treatment of Age-Related Macular Degeneration. , 2015, American journal of ophthalmology.
[26] K. Kadonosono,et al. Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration. , 2016, American journal of ophthalmology.
[27] Aaron Y. Lee,et al. Common variants near FRK/COL10A1 and VEGFA are associated with advanced age-related macular degeneration , 2011, Human molecular genetics.
[28] G. Ying,et al. Outer retinal tubulation in the comparison of age-related macular degeneration treatments trials (CATT). , 2014, Ophthalmology.
[29] A. Tsujikawa,et al. Retinal Pigment Epithelial Atrophy in Neovascular Age-Related Macular Degeneration After Ranibizumab Treatment. , 2016, American journal of ophthalmology.
[30] R. Guymer,et al. Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study. , 2015, Ophthalmology.
[31] R. Guymer,et al. Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration. , 2013, Ophthalmology.
[32] W. Wood,et al. A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration , 2013, Clinical ophthalmology.
[33] K. Horie-Inoue,et al. Complement factor H and high-temperature requirement A-1 genotypes and treatment response of age-related macular degeneration. , 2011, Ophthalmology.
[34] M. Nardi,et al. Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. , 2012, Pharmacogenomics.
[35] Glenn J Jaffe,et al. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. , 2015, Ophthalmology.
[36] Arto Luoma,et al. The IL-8, VEGF, and CFH polymorphisms and bevacizumab in age-related macular degeneration. , 2014, Ophthalmology.
[37] I. Chowers,et al. Association of complement factor H Y402H polymorphism with phenotype of neovascular age related macular degeneration in Israel , 2008, Molecular vision.
[38] R. Avery,et al. Common variant in VEGFA and response to anti-VEGF therapy for neovascular age-related macular degeneration. , 2013, Current molecular medicine.
[39] M. Brantley,et al. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. , 2007, Ophthalmology.
[40] A. Tsujikawa,et al. Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment. , 2011, American journal of ophthalmology.
[41] Gary C. Brown,et al. ASSOCIATION BETWEEN HIGH-RISK DISEASE LOCI AND RESPONSE TO ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT FOR WET AGE-RELATED MACULAR DEGENERATION , 2012, Retina.
[42] G. Ying,et al. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. , 2015, Ophthalmology.
[43] S. Harding,et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study. , 2013, Ophthalmology.
[44] Dennis Andersson,et al. A retrospective cohort study , 2018 .
[45] B. J. Klevering,et al. Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration. , 2012, Ophthalmology.
[46] S. Teper,et al. Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration , 2010, Molecular vision.
[47] Masahiro Miyake,et al. Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy , 2015, Graefe's Archive for Clinical and Experimental Ophthalmology.
[48] M. Sagong,et al. Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population , 2013, Molecular vision.
[49] R. Neal. PROJECT ADMINISTRATION , 2009 .
[50] Kang Zhang,et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). , 2013, Ophthalmology.
[51] Yonghua Hu,et al. Predictors of Visual Response to Intravitreal Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration , 2013, Journal of ophthalmology.
[52] K. Horie-Inoue,et al. CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration , 2010, Journal of ocular biology, diseases, and informatics.